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Abstract
Rationale
Understanding the reliability and repeatability of clinical measurements used in the diagno-
sis, treatment and monitoring of disease progression is of critical importance across all disci-
plines of clinical practice and in clinical trials to assess therapeutic efficacy and safety.
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Objectives
Our goal is to understand normal variability for assessing true changes in health status and
to more accurately utilize this data to differentiate disease characteristics and outcomes.
Methods
Our study is the first study designed entirely to establish the repeatability of a large number
of instruments utilized for the clinical assessment of COPD in the same subjects over the
same period. We utilized SPIROMICS participants (n = 98) that returned to their clinical cen-
ter within 6 weeks of their baseline visit to repeat complete baseline assessments. Demo-
graphics, spirometry, questionnaires, complete blood cell counts (CBC), medical history,
and emphysema status by computerized tomography (CT) imaging were obtained.
Results
Pulmonary function tests (PFTs) were highly repeatable (ICC’s >0.9) but the 6 minute walk
(6MW) was less so (ICC = 0.79). Among questionnaires, the Saint George’s Respiratory
Questionnaire (SGRQ) was most repeatable. Self-reported clinical features, such as
exacerbation history, and features of chronic bronchitis, often produced kappa values <0.6.
Reported age at starting smoking and average number of cigarettes smoked were modestly
repeatable (kappa = 0.76 and 0.79). Complete blood counts (CBC) variables produced intra-
class correlation coefficients (ICC) values between 0.6 and 0.8.
Conclusions
PFTs were highly repeatable, while subjective measures and subject recall were more vari-
able. Analyses using features with poor repeatability could lead to misclassification and out-
come errors. Hence, care should be taken when interpreting change in clinical features
based on measures with low repeatability. Efforts to improve repeatability of key clinical fea-
tures such as exacerbation history and chronic bronchitis are warranted.
Introduction
The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) is
an observational study of 2,981 participants including: healthy never-smokers, ever-smokers
(> 20 pack/years) with preserved PFTs, and individuals with COPD classified as mild-moder-
ate or severe by PFTs designed to aid in the future development of therapies for COPD [1].
The Repeatability Substudy embedded in SPIROMICS consisted of 98 participants who volun-
teered to return within 2–6 weeks to repeat their baseline visit. We designed this Substudy to
quantify baseline, within-person variation, including measurement errors. The 2–6 week win-
dow of the SPIROMICS Repeatability Substudy is considered short enough to avoid changes
due to disease progression, yet long enough to minimize any learning effect from the initial
visit. Assessing the severity of COPD utilizes a number of objective (PFTs, 6-min walk dis-
tance), subjective [modified medical research council (mMRC) dyspnea, COPD assessment
test (CAT)] and patient recall (number of exacerbations) measures utilized in determining dis-
ease progression, risk of exacerbations and treatment effects. Consistency of clinical assess-
ments during periods of disease stability is critical to interpretation, but often goes unreported.
Reliability of COPD Measures
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This report adds to recent reports on functional tests in COPD [2] by describing the repeat-
ability of the selected assessments and their potential impact on assessments of COPD used in
classifying severity, stability and progression. Some of the results of this study have been previ-
ously reported in the form of an abstract [3].
Methods
SPIROMICS is a prospective cohort study that enrolled 2981 participants at 11 clinical sites.
Extensive coordinator training, monitoring and follow-up was provided to assure consistency
across all sites. All subjects were age 40 to 80 years and willing to undergo the extensive study
procedures. Exclusion criteria included BMI>40 kg/m2, cognitive dysfunction and other lung
disease or clinically significant cardiovascular disease that would limit the interpretability of
the measures. A history of asthma was exclusionary only for never-smokers. The full SPIRO-
MICS study design and inclusion and exclusion criteria have been reported [1], and the
Repeatability dataset is available upon request (www.spiromics.org).
The SPIROMICS Repeatability Substudy comprised 98 subjects from the largest clinical
sites, who repeated their entire baseline evaluation 2–6 weeks after their initial visit. Subjects
experiencing an exacerbation between the baseline and repeat study visits were excluded from
this analysis. We separated the evaluations into A) objective measures [PFTs, six minute walk
distance and CBC], B) measures dependent on patient recall [medical history including previ-
ous lung disease diagnosis, smoking history and exacerbations] and C) subjective evaluations
[CAT[4], SGRQ [5], Functional Assessment of Chronic Illness Therapy-Fatigue [6] (FACIT-F)
Score, Pittsburg Sleep Quality Index [7] (PSQ), and Medical Outcomes SF-12 [8]]. PFTs were
conducted pre- and post- bronchodilation (BD) (4 puffs of Albuterol sulfate HFA plus 4 puffs
of Ipratropium bromide HFA). Withholding bronchodilators was not required; time from last
administration was recorded. We evaluated the repeatability of a diagnosis of chronic bronchi-
tis (CB) using: 1) patient recall of being diagnosed with CB by a health care professional; or 2)
the classic definition of chronic cough and sputum production for at least 3 months/year for
the last two consecutive years[9]; and 3) from the SGRQ questions regarding cough and
phlegm (cough and phlegm production several days a week or almost every day)[10]. Emphy-
sema was assessed by 1) recall of a diagnosis by a health care professional and 2) diagnosed
from volumetric multidetector-row computed tomography (MDCT) of the lungs performed at
full inspiration, using an emphysema index (EI) of percent voxels in the lung field < -950 HU.
GOLD staging was calculated as reported [11]. Questionnaires were administered by a study
coordinator in person, and answered solely by the participant. All blood samples for CBC dif-
ferentials were prepared according to a standard SPIROMICS protocol and analyzed locally at
each University Laboratory. All subjects provided written informed consent, and the study
was approved by the IRB at each participating site (See S1 Study Information for additional
details).
Statistical analysis
To provide reliability measurements, we calculated intraclass correlation coefficients (ICC)
and kappa statistics for quantitative and qualitative traits (MRC breathlessness scale and cur-
rent smoking status), respectively. When a value for a trait was missing for the baseline or
repeat visits, the subject was dropped from the analysis for that trait. Bland-Altman plots were
used to visualize potential changes in reliability across the spectrum of quantitative traits. In
some cases, reliability measures were calculated for the entire Substudy cohort and for a subset
diagnosed with COPD based upon baseline PFTs.
Reliability of COPD Measures
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Results
Demographics
The Substudy subjects were predominately white males (except for never-smokers) and
non-obese. The two COPD groups were significantly older than those without airways
obstruction (p = 0.0006) (Table 1). There were no significant differences between groups
in BMI, reported pack-years smoking (excluding never-smokers) or time between visits
(28.9 ± 9.4 days, mean ± SD); among the ever-smoker groups, fewer participants with
COPD reported smoking currently. Pulmonary function differences reflect SPIROMICS
enrollment groups. Bronchodilator response, as a percent change, increased with increased
disease severity. However, the absolute change in forced expiratory volume in one second
(FEV1) was not significantly different between the strata with absolute changes in FEV1
of 172.0 ±233.4, 121.9 ± 150.0, 215.2 ± 148.0 and 216.4 ± 167.2 for strata 1–4 respectively
(p  0.314). The increasing FEV1 reversibility for stratum 3 and 4 as percent change results
from the decreasing FEV1 as disease progresses [12].
We compared demographics (age, BMI, height, weight, pack-years) and post-bronchodila-
tor PFTs by groups within the repeatability population at baseline (n = 98) to the total SPIRO-
MICS cohort (n = 2852; Repeatability Substudy subjects removed). There were no significant
differences in pack-years or any of the demographic parameters, with the exception of age in
Table 1. Demographics, PFTs and six-minute walk.
Stratum 1 Stratum 2 Stratum 3 Stratum 4
Never Smokers Non-Diseased Smokers Mild-Moderate COPD Severe COPD
N 11 18 38 31
Age 55.4 ± 6.4 56.2 ± 8.4 64.7 ± 8.3 63.3 ± 8.5
BMI 26.9 ± 4.5 29.5 ± 5.9 27.7 ± 5.1 26.6 ± 5.9
Gender, % Male 36 61 76 61
Current Smokers % 0 72 54 30
Pack Years 0 41.2 ± 19.4 47.3 ± 19.6 47.5 ± 19.0
Race, %
White 64 56 71 81
Black 18 28 21 13
Hispanic 18 5 3 6
Asian 0 6 0 0
American Indian 0 6 3 0
FVC L (% Predicted) 4.19 ± 1.30 (106.2) 3.87 ± 0.75 (97.5) 3.77 ± 1.0 (94.9) 2.92 ± 1.09 (72.7)
FEV1 L (% Predicted) 3.42 ± 1.04 (110.4) 2.99 ± 0.63 (97.7) 2.27 ± 0.71 (75.9) 1.14 ± 0.48 (38.1)
FEF25-75% L/sec (% Predicted) 3.75 ± 1.16 (130.1) 2.84 ± 0.96 (101.0) 1.16 ± 0.56 (46.2) 0.46 ± 0.37 (18.0)
FEV1 /FVC (% Predicted) 103.6 100 79.4 52.9
Bronchodilator Response (% change)+
FEV1 (n) 5.5 ± 9.9 (10) 4.8 ± 5.8 (16) 12.6 ± 12.7 (25) 24.8 ± 24.2 (11)
FVC (n) 0.06 ± 6.0 (10) 0.81 ± 3.8 (16) 11.1 ± 10.3 (25) 18.0 ± 17.7 (11)
6-Min Walk Distance (M) 486.3 ± 46.6 426.5 ± 86.8 403.3 ± 111.3 329.3 ± 135.4
Values are means ± SD; n = number of subjects used in the analysis. Stratum 1 = Non-Smokers (FVC > LLN and FEV1/FVC >0.7); Stratum 2 = Non-
Diseased Smokers (FVC > LLN and FEV1/FVC >0.7); Stratum 3 = COPD FEV1 >50% and FEV1/FVC <0.7; Stratum 4 = COPD FEV1 <50% and FEV1/FVC
<0.7. Strata 2–4 are current or former smokers with >20 pack year smoking history.
+ Analysis was restricted to subjects who had not used any long-acting bronchodilator in the past 48 hours or a LABA within the past 24 hours, Tiotropium
within the past 48 hours, a SABA within 6 hours or ipratropium within the last 8 hours of the baseline visit.
https://doi.org/10.1371/journal.pone.0184606.t001
Reliability of COPD Measures
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Non-Diseased Smokers (p = 0.05) for whom mean ages were 56 vs. 60 years for the Repeatabil-
ity Substudy and the overall cohort respectively. There was no difference between the Substudy
and entire cohort in FEV1 percent predicted.
Objective measures
PFTs were highly repeatable. A scatter plot and Bland-Altman plot for baseline and repeat visit
post-bronchodilator FEV1 are shown in Fig 1. Data for post-bronchodilator FVC, FEV1/FVC
and IC are presented in (S1 Fig). Paired differences (mean± SD) between visits were very
small for post-bronchodilator FVC (0.04±0.34L), FEV1 (0.02±0.19 L/sec), FEV1/FVC (-0.001
±0.04%), and IC (0.02±0.35 L). There was no apparent effect of severity on repeatability of
these measures.
To reduce any potential impact of control subjects on the variability of PFTs, we calculated
ICCs and the mean ± SD values utilizing only COPD subjects with an FEV1/FVC ratio <0.7
(Table 2). ICCs ranged from 0.81–0.97 for all measures, lowest for FVC and FEV1 bronchodi-
lator response. The mean value of the expiratory PFT measures on the repeat visit was slightly
larger than the baseline values. The ICCs for PFTs by GOLD stage remained >0.92 for GOLD
1–3 but decreased to 0.82 for GOLD 4 subjects (n = 9) (data not shown). Repeatability (ICC)
of absolute post- to pre- FEV1 bronchodilator response for COPD subjects was 0.87 and FVC
was 0.81.
The 6-minute walk distance (Fig 2) had lower repeatability (ICC = 0.79) compared to PFT
measures, with a mean increased distance of 18.6 meters at the repeat visit, which is below the
minimal clinically important difference (MCID) of 26 meters[13]. Subjects with the shorter
walk distances were more variable between visits. Sixteen subjects (17.8%) had a decline
greater than 26 meters and twenty-eight subjects (31.1%) had an increase of greater than 26
meters at the repeat visit. The mean MRC dyspnea score slightly improved from a mean of 1.5
to 1.3, consistent with the modest increase in 6-minute walk distance. Forty-one subjects
Fig 1. Scatterplot of baseline vs. repeat visit FEV1. Subjects are color coded by GOLD stratification (using PFT values only). GOLD 0 = red, GOLD
1 = green, GOLD 2 = Blue, GOLD 3 = orange and GOLD 4 = Purple. The solid black line is drawn as a line of identity to visualize differences between baseline
and the repeat visit. A) Correlation between the baseline and repeat visit FEV1. (r = 0.983, p<0.0001; n = 98). B) Bland-Altman plot of baseline mean post-
bronchodilator FEV1 by the difference between visits. The solid red line = the mean difference, the dotted red line is ± 1 SE and the dashed blue line is ± 1 SD.
https://doi.org/10.1371/journal.pone.0184606.g001
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(59%) had no change in dyspnea, 9 subjects (13%) increased their dyspnea score by greater
than 1 and 19 subjects (28%) reported decreased dyspnea of at least 1 grade. Total white blood
cell count ICC was 0.76 for all subjects and 0.72 for subjects with COPD supporting the assess-
ment of short-term stability of the subjects between visits.
Measures dependent on patient recall
The presence of CT defined emphysema produced highly reproducible results between visits
(Kappa = 0.91) (not shown). The repeatability of self-reported physician diagnosis of emphy-
sema was Kappa = 0.71. Patient recall of physician-diagnosed CB was similar between visits
(Kappa = 0.78), but higher than that of CB determined at baseline by the classic definition
(Kappa = 0.61). At baseline, 20 subjects (25%) met the classic CB definition, whereas SGRQ
identified 41 subjects (48%); agreement between these definitions of CB was relatively poor
(Kappa = 0.35). Recall of an asthma diagnosis by a health care professional at baseline and the
repeat visit resulted in kappa = 0.57 and Kappa = 0.40 for asthma diagnosed as a child by a
health care professional. (Table 3)
Exacerbation frequency is a commonly assessed parameter in COPD. We examined several
“definitions” of reported exacerbations including total number of exacerbations of any sever-
ity, exacerbations requiring an emergency department (ED) visit or hospitalization, and those
Table 2. Baseline and repeat visit intraclass correlation coefficients for objective measures.
Clinical Measure Baseline Repeat Visit ICC* COPD+
Pre-Bronchodilator (Mean ± SD)
FVC (l) 3.09 ± 1.10 3.17 ± 1.10 0.94
FEV1 (l) 1.57 ± 0.83 1.61 ± 0.81 0.97
FEF25-75 (l/sec) 0.73 ± 0.54 0.74 ± 0.56 0.91
PEFR (l/sec) 4.81 ± 2.24 4.95 ± 2.21 0.96
FEV1/FVC 0.49 ± 0.14 0.50 ± 0.14 0.93
SVC (l) 3.19 ± 1.15 3.29 ± 1.11 0.95
IC (l) 2.44 ± 0.85 2.51 ± 0.85 0.94
Post-Bronchodilator (Mean ± SD)
FVC (l) 3.39 ± 1.12 3.46 ± 1.08 0.95
FEV1 (l) 1.76 ± 0.84 1.81 ± 0.82 0.97
FEF25-75 (l/sec) 0.84 ± 0.59 0.85 ± 0.61 0.90
PEF (l/sec) 5.25 ± 2.31 5.39 ±2.28 0.96
SVC (l) 3.50 ± 1.17 3.59 ± 1.23 0.91
FEV1/FVC 0.51 ± 0.14 0.51 ± 0.14 0.96
IC (l) 2.65 ± 0.85 2.67 ± 0.87 0.93
Bronchodilator Response (%)++
FEV1 16.3 ± 17.6 16.1 ± 15.2 0.87
FVC 13.2 ± 13.1 11.4 ± 12.0 0.81
Six minute Walk Distance 372.10 ±126.54 394.50 ± 107.91 0.79
Means ± SD
*ICC = Intraclass Correlation
+ COPD = Strata 3&4 only
++ Bronchodilator Response calculated as [(post-BD
-
Pre-BD) / Pre-BD FEV1] x 100. Analysis was restricted to subjects who had not used any long-acting
bronchodilator in the past 48 hours or a LABA within the past 24 hours, Tiotropium within the past 48 hours, or a SABA within 6 hours or ipratropium within
the last 8 hours of the baseline and repeat visits (n = 36).
https://doi.org/10.1371/journal.pone.0184606.t002
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treated with any medication (corticosteroids or antibiotics). The repeatability of exacerbation
recall was modest, but fairly consistent across exacerbation definitions (Table 3). Repeatability
increased if the recall of an exacerbation was associated with use of a specific medication such
as a corticosteroid or antibiotic. For total exacerbations recall, 48 subjects (71%) remained
unchanged, with 59 subjects (87%) unchanged in recall of ED/hospitalization exacerbations.
Fig 2. Six minute walk distance. The subjects are color coded by GOLD classification as in Fig 1A)
Scatterplot of the six-minute walk distance at the baseline and repeat visits (r = 0.829, p<0.0001; n = 92). The
solid black line is drawn as a line of identity to visualize differences between the baseline and the repeat visits.
B) Bland-Altman plot of the mean distance for each subject (baseline and repeat) by the difference between
visits. The solid red line = the mean difference, the dotted red line is ± 1 SE and the Dashed blue line is ± 1 SD.
https://doi.org/10.1371/journal.pone.0184606.g002
Reliability of COPD Measures
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Subjective measures
Subject recall of the age started smoking, average cigarettes smoked per day over the lifetime
of smoking and calculated pack-years were evaluated. The baseline and repeat visit values for
age started smoking were 16.4 ± 4.5 and 16.0 ± 3.5 respectively (ICC = 0.76), average cigarettes
per day 25.4 ± 9.1 and 24.5 ± 9.9 (ICC = 0.79) and calculated pack-years smoked 47.4 ± 19.2
and 49.4 ± 21.6 (ICC = 0.84).
Questionnaires commonly used in COPD showed wide disparity in repeatability (Table 4).
Performance ranged from SGRQ-C total score (ICC = 0.94), to MRC dyspnea (kappa = 0.42).
The mean change in SGRQ-C between visits was 2.2 units; 34 subjects (55.7%) had no change
above the minimum clinically important difference (MCID) of 4 units (Table 5) [14]. The two
Table 3. Measures dependent of patient recall: Disease diagnosis and exacerbations.
Variable Name Kappa Statistics
N Kappa 95% CI
Emphysema HCP Diagnosed 88 0.71 0.55 0.87
CB HCP Diagnosed* 87 0.78 0.61 0.95
CB Classic definition+ 95 0.61 0.42 0.80
CB SGRQ** 82 0.61 0.44 0.78
Asthma HCP Diagnosed## 85 0.57 0.36 0.78
Asthma Child Diagnosis 84 0.40 0.10 0.69
Exacerbations in prior 12 months 68 0.42 0.23 0.61
Exacerbations Treated with Any Medications 68 0.45 0.23 0.66
Exacerbations Treated with Corticosteroids 68 0.54 0.31 0.77
Exacerbations Treated with Antibiotics 68 0.58 0.36 0.79
Exacerbations Requiring ED/Hospitalization 68 0.57 0.33 0.82
* CB–Chronic
Bronchitis Diagnosed by a Health Care Provider (HCP)
+ Chronic mucus production and cough for at least 3 months/year for 2 successive years.
** Chronic bronchitis defined as cough and phlegm production several days a week or almost every day
from the SGRQ.
## Asthma diagnosed as a child by a HCP
https://doi.org/10.1371/journal.pone.0184606.t003
Table 4. ICC values for clinical questionnaires.
Clinical Questionnaire Baseline Repeat Visit ICC* COPD
MRC Dyspnea 1.5 ± 1.1 1.3 ± 1.0 Kappa 0.42+
Bode Index 2.5 ± 2.2 2.1 ± 1.8 0.84
COPD Assessment Test (CAT) 16.3 ± 8.5 16.2 ± 7.9 0.78
SGRQ-C Total Score 41.8 ± 21.2 40.2 ± 21.5 0.94
FACIT-F Total 111.0 ± 26.1 112.1 ± 27.3 0.91
PSQ Total Score 7.0 ± 4.2 6.9 ± 4.3 0.85
Medical Outcomes SF-12
SF-12 Gen Health 25.0 ± 11.7 26.5 ± 12.0 0.68
SF-12 Physical Functioning 21.3 ± 12.8 22.7 ± 12.5 0.63
Data are Mean ± SD
*ICC = Intraclass Correlation, COPD subjects only
+ Kappa Statistic was utilized because of the categorical nature of the data
https://doi.org/10.1371/journal.pone.0184606.t004
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scores incorporated into the GOLD 2015 and 2017 [15] guidelines (CAT and MRC Dyspnea)
appeared to have modest repeatability between visits (ICC = 0.78 and kappa = 0.42, respec-
tively). Change between visits in CAT score ranged from +18 to -11. Among subjects with
COPD, 23 of 65 (35.4%) had no change in CAT score (Table 5) above the MCID (2 units). For
the MRC dyspnea score, 41 subjects (59.4%) were unchanged (Table 5).
Evaluation of GOLD classification determined solely by PFTs for the COPD subjects
demonstrated that 53 of 69 subjects (76.8%) retained their GOLD stage at the repeat visit.
(kappa = 0.75). Utilizing the GOLD symptom burden / exacerbation risk criteria [15] with
MMRC, 44 of 64 (five subjects had missing mMRC scores) subjects remained unchanged
(kappa = 0.54) and with the CAT assessment 46 of 64 (72%) remained the same (kappa = 0.58)
(Table 5).
Discussion
This formal, multi-center repeatability study, performed over an average 29-day interim in a
representative subset of the entire SPIROMICS cohort, provides an unprecedented assessment
of the variability of the instruments used to characterize COPD subjects. Repeatability of pul-
monary function testing was strongest (ICC>0.90) and subject recall of a childhood diagnosis
of asthma weakest (kappa = 0.40), consistent with a trend of greater repeatability of objective
measures relative to those dependent on participant recall or subjectivity.
Our analytic plan was designed specifically to improve estimation of the reliability of
clinically relevant predictors of COPD severity and activity. Inherent variability in a predic-
tor, due either to measurement error or to short-term biological fluctuations, may bias esti-
mates of the association between the predictor and an outcome [16]. Estimation of the
reliability of a predictor, such as the intraclass correlation, allows correction for the bias
using regression calibration. This is important in defining COPD subsets for analysis and in
evaluating disease progression.
These results relate to the complexity of what we call COPD. Historically, the disease has
been conceptualized as having a slow, often variably progressive decline in lung function. [17–
19]. However, recent data suggests that the slope of decline in FEV1% predicted slows in
advanced disease[20] and that correlations between lung function and other measures such as
exacerbations and symptoms are not always strong [21, 22]. Nevertheless, FEV1 remains the
objective gold standard for assessing disease severity, progression, and treatment efficacy. Our
finding that all PFTs had an ICC >0.90 supports the use of PFTs as a primary outcome vari-
able. These data are consistent with other reports demonstrating the high repeatability of spi-
rometric values between visits of short intervals over a range of disease severities [12, 23]. Our
Table 5. Change from baseline visit.
n Unchanged1 Increased Decreased
Total Exacerbations 68 48 (71%) 6 (9%) 14 (21%)
Exacerbations requiring ED/Hospitalization 68 59 (87%) 4 (6%) 5 (7%)
SGRQ2 84 27 (44%) 10 (16%) 24 (39%)
COPD Assessment Test (CAT)2 65 23 (35%) 21 (32%) 21 (32%)
mMRC2 98 41 (59%) 9 (13%) 19 (28%)
GOLD PFTs 69 53 (77%) 4 (6%) 12 (17%)
GOLD Combined-mMRC3 64 44 (69%) 7 (11%) 13 (20%)
GOLD Combined- CAT3 64 46 (72%) 9 (14%) 9 (14%)
Number of subjects (% of total). n = number changed >MCID: SGRQ = 4; CAT = 2; mMRC = 1. Increase indicates a change from A to B, B to C or C to D
https://doi.org/10.1371/journal.pone.0184606.t005
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mean change in FEV1 (20.4 mL overall, 30.7 mL for men, 1.9 mL for women), compares favor-
ably with results from the Lung Health Study (LHS) at screening visits 21 days apart, which
reported a coefficient of variation of 4% (changes of 14.3 mL for men, 4.5 mL for women)[23].
Similar results were reported for FEV1 in the National Emphysema Treatment Trial (NETT)
for PFTs conducted within 60 days of each other [12]. We extend those finding by showing
that IC, an important driver of exercise limitation, was as repeatable as other spirometric
parameters (ICC = 0.93) [24–26]. IC decreases during exercise in COPD, and is responsive to
bronchodilator therapy [27, 28]. Bronchodilator response is influenced by many factors
including pre-bronchodilator FEV1 and actual withholding of confounding bronchodilator
medications [29]. In our study, withholding bronchodilators was not required, but extensive
questions were asked on drug use and time of administration. Our reported bronchodilator
response was calculated in subjects who withheld bronchodilators (65 out of 98 subjects) for
sufficient time before PFT testing, potentially representing a more accurate picture of bron-
chodilator responsiveness.
Fully assessing the full clinical picture of COPD requires additional factors and composite
scores dependent on patient recall and subjective evaluation [30]. We found that most of the
validated questionnaires had lower ICCs than the PFTs. Among them, the most repeatable
was the SGRQ-C, which is tailored for use in chronic airflow limitation and is responsive to
changes in disease activity [31, 32]. Repeatability of SGRQ-C has been reported as ICC = 0.92
in 40 subjects evaluated at a 2 week interval [31], in good agreement with our results. Each
questionnaire has a different specified recall time period, ranging from none specified (SGRQ-
C) to 7 days for the FACIT-F and current assessment for the CAT, which could affect repeat-
ability. Nevertheless, we found significant correlations between the utilized questionnaire
scores (data not shown), suggesting that they are measuring similar aspects of the disease.
This relationship is not surprising because all aim to assess the functional impact of COPD
on quality of life. Our finding that repeatability of subject recall of age started smoking was
similar to assessing average number of cigarettes smoked over their life-time, is consistent
with an extensive internet based survey of tobacco exposure and risk [33]. They found age first
started smoking cigarettes slightly more consistent (ICC = 0.85) than calculated pack-years
(ICC = 0.76). Despite our finding of a few subjects with very different recall of pack-years
smoked, overall, pack-years seems relatively reliable, but of unknown accuracy.
Finally, these results provide insights into the use of patient recall of exacerbation history to
predict susceptibility to future exacerbations. Our results on short-term repeatability of recall-
ing COPD exacerbations before enrollment (total exacerbations, kappa = 0.42), was somewhat
higher when defined by treatment with corticosteroids or antibiotics (kappa = 0.54 and 0.58,
respectively). These data are similar to reported concordance of cardiovascular events, in that
the more defined the event, the greater the reliability [34]. It was surprising that recall of exac-
erbations requiring an emergency department visit or hospitalization was not significantly
higher. The frequency of exacerbations, and not the severity, may be the most important factor
in patient recall inaccuracies [35]. In the ECLIPSE study, patient recall of the number of exac-
erbations in the year before enrollment was the single strongest predictor of future exacerba-
tions [22] highlighting the importance of exacerbation recall for COPD studies. However, our
current results imply that using patient recall of exacerbation frequency as an enrollment crite-
rion for short-term clinical trials may lead to substantial variability in outcomes. The inaccu-
racy of patient recall of exacerbation rate was recently highlighted when compared with single-
physician chart review or a central adjudication committee [35]. It is surprising that recall of
hospitalization or ED visit was not consistent, highlighting the need for exacerbation docu-
mentation in determining GOLD status and associated treatment choices.
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A key feature of our analysis is its implications for the GOLD combined assessment of
COPD, which is employed both for assessment of disease severity and for treatment recom-
mendations. We found a higher reliability (as judged by ICC) for the GOLD classification
using PFTs. Incorporation of symptom scores (MMRC and CAT) into GOLD classification
for symptoms and exacerbation risk increases variability between visits. Using the 2015 GOLD
combined assessment criteria, 31% of the subjects changed by at least one GOLD level using
GOLD-MMRC and 18% changed using GOLD-CAT. We recognize that there are two possible
interpretations of the more limited repeatability of symptom-based scores compared to PFTs.
It is possible that symptom scores are more sensitive than PFTs for clinical changes and pro-
vide a more sensitive indicator of current illness. This is reflected in the updated GOLD crite-
ria [15, 36]. Symptom scores also reflect an integrated assessment of a multi-organ disease and
comorbidities that are common in these subjects. However, the observation that parameters
dependent upon subject recall also have poorer consistency upon repeat evaluation suggests
that a component of the variation in symptoms, in the absence of changes in spirometry, may
be a reflection of the subjective nature of the assessment. Further work is required to best
delineate the precision of change in symptom scores as endpoints for clinical trials in COPD.
As with all studies, there are limitations. This Repeatability Substudy evaluated differences
in participant response over an interval of 28.9±9.4 days (mean ± SD). We did not adjust for
variation in time between visits. It is also unknown how a longer or shorter time would corre-
late with the results reported here. Though demographics of the Substudy were consistent with
the total SPIROMICS cohort, only 7 of the 11 clinical centers contributed data to this Sub-
study, so these results may not reflect repeatability across all of the centers. Also, we cannot
rule out an effect of training [37], as some measures improved at the repeat visit. Perhaps most
crucially, these subjects may not be representative of the general COPD population.
In summary, we demonstrate that in the SPIROMICS Repeatability Substudy, the repeatabil-
ity of supervised objective measures was strongest. PFTs demonstrated the highest ICC values
and recall of exacerbations had some of the lowest kappa statistics. Reliability of questionnaires
was consistent with literature reports. However, significant numbers of subjects had variation
between visits above recommended MCIDs, which notably affected GOLD staging for symp-
toms and exacerbation risk incorporating either the CAT or MMRC. Within-subject variability
must be accounted for in interpreting phenotype assignments or disease progression. We feel
that these data will aid the design and interpretation of longitudinal COPD studies. Examining
multiple types of parameters widely used in COPD assessment should also help in the develop-
ment of clinical practice guidelines.
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